1. Predicting development of adolescent drinking behaviour from whole brain structure at 14 years of age.
- Author
-
Kühn S, Mascharek A, Banaschewski T, Bodke A, Bromberg U, Büchel C, Quinlan EB, Desrivieres S, Flor H, Grigis A, Garavan H, Gowland PA, Heinz A, Ittermann B, Martinot JL, Nees F, Papadopoulos Orfanos D, Paus T, Poustka L, Millenet S, Fröhner JH, Smolka MN, Walter H, Whelan R, Schumann G, Lindenberger U, and Gallinat J
- Subjects
- Adolescent, Alcoholism physiopathology, Alcohols toxicity, Brain drug effects, Brain physiopathology, Brain Mapping, Caudate Nucleus drug effects, Caudate Nucleus physiopathology, Cerebellum drug effects, Cerebellum physiopathology, Female, Humans, Magnetic Resonance Imaging, Male, Underage Drinking prevention & control, Alcoholism diagnostic imaging, Brain diagnostic imaging, Caudate Nucleus diagnostic imaging, Cerebellum diagnostic imaging
- Abstract
Adolescence is a common time for initiation of alcohol use and development of alcohol use disorders. The present study investigates neuroanatomical predictors for trajectories of future alcohol use based on a novel voxel-wise whole-brain structural equation modeling framework. In 1814 healthy adolescents of the IMAGEN sample, the Alcohol Use Disorder Identification Test (AUDIT) was acquired at three measurement occasions across five years. Based on a two-part latent growth curve model, we conducted whole-brain analyses on structural MRI data at age 14, predicting change in alcohol use score over time. Higher grey-matter volumes in the caudate nucleus and the left cerebellum at age 14 years were predictive of stronger increase in alcohol use score over 5 years. The study is the first to demonstrate the feasibility of running separate voxel-wise structural equation models thereby opening new avenues for data analysis in brain imaging., Competing Interests: SK, AM, AB, UB, EQ, SD, HF, AG, HG, PG, AH, BI, JM, FN, DP, TP, LP, SM, JF, MS, HW, RW, GS, UL, JG No competing interests declared, TB Has served as an advisor or consultant to Bristol-Myers Squibb, Desitin Arzneimittel, Eli Lilly, Medice, Novartis, Pfizer, Shire, UCB, and Vifor Pharma; he has received conference attendance support, conference support, or speaking fees from Eli Lilly, Janssen McNeil, Medice, Novartis, Shire, and UCB; and he is involved in clinical trials conducted by Eli Lilly, Novartis, and Shire; the present work is unrelated to these relationships. CB Reviewing editor, eLife, (© 2019, Kühn et al.)
- Published
- 2019
- Full Text
- View/download PDF